Novartis flu vaccine ban lifted in under 3 weeks
This article was originally published in Scrip
The Italian medicines agency AIFA has lifted the precautionary temporary ban on Novartis's flu vaccines after tests showed that there were no quality defects with commercialised lots. AIFA's latest move follows the lifting of bans imposed by regulators in Switzerland and Canada on 31 October and in Singapore on 2 November after they also concluded that there were no quality concerns (scripintelligence.com, 2 November 2012).
You may also be interested in...
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.